Validation of the 12-gene colon cancer Recurrence Score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin

Journal of Clinical Oncology

Volumn 31, Issue 36, 2013, Pages 4512-4519

  Yothers, Greg ^a,b   O'Connell, Michael J ^a   Lee, Mark ^d   Lopatin, Margarita ^d   Clark Langone, Kim M ^d   Millward, Carl ^e   Paik, Soonmyung ^a   Sharif, Saima ^a,c   Shak, Steven ^d   Wolmark, Norman ^a,c  

^a National Surgical Adjuvant Breast and Bowel Project (NSABP) Operations and Biostatistical Centers   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

^d Genomic Health   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; COLON CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; SCORING SYSTEM; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; SURVIVAL; TUMOR RECURRENCE; VALIDATION STUDY; COLON TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MISMATCH REPAIR; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS;

EID: 84894437676     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.3116     Document Type: Article

References (30)

1. Kuebler JP, Wieand HS, O'Connell MJ, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 25:2198-2204, 2007 (Pubitemid 46954643)
2. Yothers G, O'Connell MJ, Allegra CJ, et al: Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29:3768-3774, 2011
3. André T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004 (Pubitemid 38702845)
4. André T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116, 2009
5. Haller DG, Tabernero J, Maroun J, et al: Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29:1465-1471, 2011
6. Weickhardt A, Wells K, Messersmith W: Oxaliplatin-induced neuropathy in colorectal cancer. J Oncol 2011:201593, 2011
7. Hoff PM, Saad ED, Costa F, et al: Literature review and practical aspects on the management of oxaliplatin-associated toxicity. Clin Colorectal Cancer 11:93-100, 2012
8. Kelley RK, Venook AP: Prognostic and predictive markers in stage II colon cancer: Is there a role for gene expression profiling? Clin Colorectal Cancer 10:73-80, 2011
9. Braun MS, Seymour MT: Balancing the efficacy and toxicity of chemotherapy in colorectal cancer. Ther Adv Med Oncol 3:43-52, 2011
10. Wilkinson NW, Yothers G, Lopa S, et al: Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: Pooled analysis of NSABP C-01 through C-05 - A baseline from which to compare modern adjuvant trials. Ann Surg Oncol 17:959-966, 2010
11. Vicuna B, Benson AB 3rd: Adjuvant therapy for stage II colon cancer: Prognostic and predictive markers. J Natl Compr Canc Netw 5:927-936, 2007 (Pubitemid 350069531)
12. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines for Oncology: Colon Cancer v3.2012. Fort Washington, PA, National Comprehensive Cancer Network, 2012
13. Fariña Sarasqueta A, van Lijnschoten G, Lemmens VE, et al: Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: Are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers? Mol Diagn Ther 15:277-283, 2011
14. Harradine KA, Kassner M, Chow D, et al: Functional genomics reveals diverse cellular processes that modulate tumor cell response to oxaliplatin. Mol Cancer Res 9:173-182, 2011
15. Shirota Y, Stoehlmacher J, Brabender J, et al: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19:4298-4304, 2001 (Pubitemid 33096777)
16. Jensen NF, Smith DH, Nygård SB, et al: Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer. Scand J Gastroenterol 47:340-355, 2012
17. O'Connell MJ, Lavery I, Yothers G, et al: Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 28:3937-3944, 2010
18. Gray RG, Quirke P, Handley K, et al: Validation study of a quantitative multigene reverse transcriptasepolymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 29:4611-4619, 2011
19. Venook AP, Niedzwiecki D, Lopatin M, et al: Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581. J Clin Oncol 29, 2011 (suppl; abstr 3518)
20. Clark-Langone KM, Sangli C, Krishnakumar J, et al: Translating tumor biology into personalized treatment planning: Analytical performance characteristics of the Oncotype DX Colon Cancer Assay. BMC Cancer 10:691, 2010
21. Greene FL, American Joint Committee on Cancer, American Cancer Society: AJCC Cancer Staging Manual (ed 6). New York, NY, Springer, 2002
22. Compton CC, Fielding LP, Burgart LJ, et al: Prognostic factors in colorectal cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:979-994, 2000 (Pubitemid 30602039)
23. Grambsch PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 8:515-526, 1994
24. Therneau TM, Grambsch PM: Modeling Survival Data: Extending the Cox Model. New York, NY, Springer, 2001
25. Sinicrope FA, Foster NR, Thibodeau SN, et al: DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5- fluorouracil-based adjuvant therapy. J Natl Cancer Inst 103:863-875, 2011
26. Park SB, Lin CS, Krishnan AV, et al: Long-term neuropathy after oxaliplatin treatment: Challenging the dictum of reversibility. Oncologist 16:708-716, 2011
27. Jackson McCleary NA, Meyerhardt JA, Green E, et al: Impact of older age on the efficacy of newer adjuvant therapies in 12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database. J Clin Oncol 27:170s, 2009 (suppl; abstr 4010)
28. O'Connell M, Lavery I, Gray R, et al: Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score. J Clin Oncol 28:261s, 2010 (suppl; abstr 3503)
29. Sargent DJ, Marsoni S, Monges G, et al: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28:3219-3226, 2010
30. Kelley RK, Van Bebber SL, Phillips KA, et al: Personalized medicine and oncology practice guidelines: A case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw 9:13-25, 2011